Treating the brain cancer glioblastoma (GBM) demands more than conventional strategies due to a mix of factors including the cancer’s genetic complexity, invasive growth, and immune resistance. A new ...

The field of cancer immunology has seen significant advancements in recent years, particularly with the emergence of immunotherapy as a key pillar in the ...

DOC1021 is a first-in-class, patient-derived double-loaded dendritic cell therapy that combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient's dendritic ...

Overview of the manufacturing process of personalized neoantigen-based DC vaccines. A typical basic process of manufacturing neoantigen-based DC vaccines by using monocyte-derived dendritic cells is ...

Favorable safety profile and encouraging early efficacy signals support advancement to Phase II trial of dendritic cell vaccine for the treatment of glioblastoma. HOUSTON, June 2, 2025 /PRNewswire/ -- ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...

The immunotherapy is made with a patient's dendritic cells combined with mRNA and proteins prepared from freshly obtained patient tumor specimens. The unique double loading approach, which mimics a ...